Diagnosing the decline in pharmaceutical R&D efficiency
The DOI matches its Crossref record; 85 of the 85 references it cites were found in a registry or an index.
Abstract
The past 60 years have seen huge advances in many of the scientific, technological and managerial factors that should tend to raise the efficiency of commercial drug research and development (RD). Yet the number of new drugs approved per billion US dollars spent on RD has halved roughly every 9 years since 1950, falling around 80-fold in inflation-adjusted terms. There have been many proposed solutions to the problem of declining RD efficiency. However, their apparent lack of impact so far and the contrast between improving inputs and declining output in terms of the number of new drugs make it sensible to ask whether the underlying problems have been correctly diagnosed. Here, we discuss four factors that we consider to be primary causes, which we call the 'better than the Beatles' problem; the 'cautious regulator' problem; the 'throw money at it' tendency; and the 'basic research-brute force' bias. Our aim is to provoke a more systematic analysis of the causes of the decline in RD efficiency.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“For over fifty years, the pharmaceutical industry has seen the cost of developing drugs increase exponentially from tens of millions in the 1950s to billions of dollars today, even when the data is adjusted for inflation [1].”
From Drug design on quantum computers (2024) · doi:10.1038/s41567-024-02411-5 · cites this paper as [1]
Citations
Cites
Collective dynamics of ‘small-world’ networks
Watts, D. J., & Strogatz, S. H. (1998) · Nature · doi:10.1038/30918 · Cited by 43,060
Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(00)00129-0 · Cited by 18,139
OLSSON, A. G., McMurray, J. J. V., Thorgeirsson, G., Spaulding, C. M., Slattery, J., Pyörälà, K., Færgeman, O., Wright, R. S., Berg, K. M., Wilhelmsen, L., et al. (1994) · The Lancet · Cited by 8,467
Improved survival with vemurafenib in melanoma with BRAF V600E mutation
Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., Dummer, R., Garbe, C., Testori, A., Maio, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103782 · Cited by 7,720
Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer
Soda, M., Choi, Y. L., Enomoto, M., Takada, S., Yamashita, Y., Ishikawa, S., Fujiwara, S.-I., Watanabe, H., Kurashina, K., Hatanaka, H., et al. (2007) · Nature · doi:10.1038/nature05945 · Cited by 5,439 · cited 1×
“It is hard to look at the genesis of drugs like crizotini”
BackgroundCan the pharmaceutical industry reduce attrition rates?
Kola, I., & Landis, J. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1470 · Cited by 4,167
SCANDINAVIANSIMVASTATINSURVIVAL (1994) · The Lancet · doi:10.1016/s0140-6736(94)90566-5 · Cited by 3,645
How to improve R&D productivity: the pharmaceutical industry's grand challenge
Paul, S. M., Mytelka, D. S., Dunwiddie, C. T., Persinger, C. C., Munos, B. H., Lindborg, S. R., & Schacht, A. L. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3078 · Cited by 3,566
How many drug targets are there?
Overington, J. P., Al-Lazikani, B., & Hopkins, A. L. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2199 · Cited by 3,505
Hopkins, A. L., & Groom, C. R. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd892 · Cited by 3,305 · cited 1×
“First, estimates of the number of potential drug target”
Background
Research works printed but not linked: 6
- Ruffolo, R. R. Engineering success: Wyeth redefines its research & development organisation. Drug Discovery World website [online] , (2005).
- Young, M. P. Prediction v Attrition. Drug Discovery World website [online] , (2008).
- Healy, D. The Psychopharmacologists: Volume 2 93–118 (Hodder Arnold, London, 1999).
- Healy, D. The Psychopharmacologists: Volume 2 259–264 (Hodder Arnold, London, 1999).
- Mathieu, M. P. (ed.) Parexel's Bio/Pharmaceutical R&D Statistical Sourcebook 2010/2011 163–261 (Barnett International, Needham, Massachusetts, 2010).
- Munos, B. How to avert biopharma's R&D crisis. In Vivo 29, 2011800050 (2011).
Cited by
Drug repurposing: progress, challenges and recommendations
Pushpakom, S., Iorio, F., Eyers, P. A., Escott, K. J., Hopper, S., Wells, A., Doig, A., Guilliams, T., Latimer, J., McNamee, C., et al. (2019) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.168 · Cited by 4,718
Discovery and resupply of pharmacologically active plant-derived natural products: A review
Atanasov, A. G., Waltenberger, B., Pferschy-Wenzig, E.-M., Linder, T., Wawrosch, C., Uhrin, P., Temml, V., Wang, L., Schwaiger, S., Heiss, E. H., et al. (2015) · Biotechnology Advances · doi:10.1016/j.biotechadv.2015.08.001 · Cited by 2,904
“The obtained results, however, did not meet the expectations as evident in a declining number of new drugs reaching the market (David et al., 2015; Kingston, 2011; Scannell et al., 2012).”
BackgroundResultInfluentialLessons learned from the fate of AstraZeneca's drug pipeline: a five-dimensional framework
Cook, D., Brown, D., Alexander, R., March, R., Morgan, P., Satterthwaite, G., & Pangalos, M. N. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4309 · Cited by 1,344
“11 (5) Evidence from previous phase not robust enough”
BackgroundNetwork pharmacology: curing causal mechanisms instead of treating symptoms
Nogales, C., Mamdouh, Z. M., List, M., Kiel, C., Casas, A. I., & Schmidt, H. H. H. W. (2022) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2021.11.004 · Cited by 1,201
Artificial Intelligence in Pharmaceutical Technology and Drug Delivery Design
Vora, L. K., Gholap, A. D., Jetha, K., Thakur, R. R. S., Solanki, H. K., & Chavda, V. P. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15071916 · Cited by 1,061
“The global outbreak of COVID-19 has caused significant disruptions to various operations worldwide, including ongoing clinical trials (Chavda, et al, 2023).”
BackgroundOrgans-on-chips at the frontiers of drug discovery
Esch, E. W., Bahinski, A., & Huh, D. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4539 · Cited by 1,185
The Current State of Peptide Drug Discovery: Back to the Future?
Henninot, A., Collins, J. C., & Nuss, J. M. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00318 · Cited by 1,113
Organs-on-chips: into the next decade
Low, L. A., Mummery, C., Berridge, B. R., Austin, C. P., & Tagle, D. A. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0079-3 · Cited by 1,029
Artificial intelligence in drug development: Present status and future prospects
Mak, K.-K., & Pichika, M. R. (2019) · Drug Discovery Today · doi:10.1016/j.drudis.2018.11.014 · Cited by 1,018
Are Ideas Getting Harder to Find?
Bloom, N., Jones, C. I., Van Reenen, J., & Webb, M. (2020) · American Economic Review · doi:10.1257/aer.20180338 · Cited by 1,002
Schneider, G. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.232 · Cited by 910
Structure and dynamics of molecular networks: A novel paradigm of drug discovery
Csermely, P., Korcsmáros, T., Kiss, H. J. M., London, G., & Nussinov, R. (2013) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2013.01.016 · Cited by 892
“However, it is worth to note that looking only at the number of new drugs without considering their therapeutic value omits an important factor in the analysis (Austin, 2006; Overington et al., 2006; Chong & Sullivan, 2007; Bunnage, 2011; Edwards et al., 2011; Scannell et al., 2012).”
BackgroundRegulated cell death (RCD) in cancer: key pathways and targeted therapies
Peng, F., Liao, M., Qin, R., Zhu, S., Peng, C., Fu, L., Chen, Y., & Han, B. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01110-y · Cited by 832
“MOA is of great significance in evaluating the efficacy and toxicity of compounds.(376) A study found that altretamine is a new GPX4 inhibitor similar to sulfasalazine through the prediction-based MOA analysis of detecting mechanism of action by network dysregulation (demand) and combined with experiments, inhibiting…”
BackgroundAn overview of the synthetic routes to the best selling drugs containing 6-membered heterocycles
Baumann, M., & Baxendale, I. R. (2013) · Beilstein Journal of Organic Chemistry · doi:10.3762/bjoc.9.265 · Cited by 841
Oral Druggable Space beyond the Rule of 5: Insights from Drugs and Clinical Candidates
Doak, B. C., Over, B., Giordanetto, F., & Kihlberg, J. (2014) · Chemistry & Biology · doi:10.1016/j.chembiol.2014.08.013 · Cited by 835
Seyhan, A. A. (2019) · Translational Medicine Communications · doi:10.1186/s41231-019-0050-7 · Cited by 713
Can you teach old drugs new tricks?
Nosengo, N. (2016) · Nature · doi:10.1038/534314a · Cited by 729
Validating therapeutic targets through human genetics
Plenge, R. M., Scolnick, E. M., & Altshuler, D. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd4051 · Cited by 712
Generating Theory by Abduction
Sætre, A. S., & Van de Ven, A. (2021) · Academy of Management Review · doi:10.5465/amr.2019.0233 · Cited by 608
Microengineered physiological biomimicry: Organs-on-Chips
Huh, D., Torisawa, Y.-S., Hamilton, G. A., Kim, H. J., & Ingber, D. E. (2012) · Lab on a Chip · doi:10.1039/c2lc40089h · Cited by 667
Zitnik, M., Nguyen, F., Wang, B., Leskovec, J., Goldenberg, A., & Hoffman, M. M. (2019) · Information Fusion · doi:10.1016/j.inffus.2018.09.012 · Cited by 675
Artificial intelligence for clinical trial design
Harrer, S., Shah, P., Antony, B., & Hu, J. (2019) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2019.05.005 · Cited by 672
“Although pharma and biotechnology companies have continuously increased R&D investment for decades, the number of new drugs gaining regulatory approval per billion USD spent has halved approximately every 9 years [1].”
BackgroundMultifaceted Roles of Disulfide Bonds. Peptides as Therapeutics
Góngora-Benítez, M., Tulla-Puche, J., & Albericio, F. (2014) · Chemical Reviews · doi:10.1021/cr400031z · Cited by 655
Systematic integration of biomedical knowledge prioritizes drugs for repurposing
Himmelstein, D. S., Lizee, A., Hessler, C., Brueggeman, L., Chen, S. L., Hadley, D., Green, A., Khankhanian, P., & Baranzini, S. E. (2017) · eLife · doi:10.7554/elife.26726 · Cited by 666
“mal strategy from both a business and public health perspective (Scannell et al., 2012).”
BackgroundThe High Cost of Prescription Drugs in the United States: Origins and Prospects for Reform
Kesselheim, A. S., Avorn, J., & Sarpatwari, A. (2016) · JAMA · doi:10.1001/jama.2016.11237 · Cited by 592
Macrocyclic Drugs and Clinical Candidates: What Can Medicinal Chemists Learn from Their Properties?
Giordanetto, F., & Kihlberg, J. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm400887j · Cited by 563
Influenza virus-induced lung injury: pathogenesis and implications for treatment
Herold, S., Becker, C., Ridge, K. M., & Budinger, G. R. S. (2015) · European Respiratory Journal · doi:10.1183/09031936.00186214 · Cited by 503
The discovery of first-in-class drugs: origins and evolution
Eder, J., Sedrani, R., & Wiesmann, C. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4336 · Cited by 514
“12% (9) 3% (2) 1% (1) 22% (17) 10% (8) 5% (4) 21% (16) 6% (2)”
Phenotypic screening in cancer drug discovery — past, present and future
Moffat, J. G., Rudolph, J., & Bailey, D. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4366 · Cited by 507
Ensemble Docking in Drug Discovery
Amaro, R. E., Baudry, J., Chodera, J., Demir, Ö., McCammon, J. A., Miao, Y., & Smith, J. C. (2018) · Biophysical Journal · doi:10.1016/j.bpj.2018.02.038 · Cited by 479
Passarelli, M. K., Pirkl, A., Moellers, R., Grinfeld, D., Kollmer, F., Havelund, R., Newman, C. F., Marshall, P. S., Arlinghaus, H., Alexander, M. R., et al. (2017) · Nature Methods · doi:10.1038/nmeth.4504 · Cited by 463
Drug repositioning: a brief overview
Jourdan, J.-P., Bureau, R., Rochais, C., & Dallemagne, P. (2020) · Journal of Pharmacy and Pharmacology · doi:10.1111/jphp.13273 · Cited by 470
“The main aim of drug repositioning is to combat the attrition and rising costs which, according to ‘Eroom’s law’,([23]) are having a dramatic effect on the number of new drugs entering the pharmaceuticals market.”
BackgroundImpact of a five-dimensional framework on R&D productivity at AstraZeneca
Morgan, P., Brown, D. G., Lennard, S., Anderton, M. J., Barrett, J. C., Eriksson, U., Fidock, M., Hamrén, B., Johnson, A., March, R. E., et al. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.244 · Cited by 452
Shultz, M. D. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00686 · Cited by 434
Induced pluripotent stem cells: the new patient?
Bellin, M., Marchetto, M. C., Gage, F. H., & Mummery, C. L. (2012) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3448 · Cited by 431
CRISPR in cancer biology and therapy
Katti, A., Diaz, B. J., Caragine, C. M., Sanjana, N. E., & Dow, L. E. (2022) · Nature Reviews Cancer · doi:10.1038/s41568-022-00441-w · Cited by 424
Low-N protein engineering with data-efficient deep learning
Biswas, S., Khimulya, G., Alley, E. C., Esvelt, K. M., & Church, G. M. (2021) · Nature Methods · doi:10.1038/s41592-021-01100-y · Cited by 422
Evolution of strategies to improve preclinical cardiac safety testing
Gintant, G., Sager, P. T., & Stockbridge, N. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2015.34 · Cited by 407
New Modalities for Challenging Targets in Drug Discovery
Valeur, E., Guéret, S. M., Adihou, H., Gopalakrishnan, R., Lemurell, M., Waldmann, H., Grossmann, T. N., & Plowright, A. T. (2017) · Angewandte Chemie International Edition · doi:10.1002/anie.201611914 · Cited by 382
Riedl, A., Schlederer, M., Pudelko, K., Stadler, M., Walter, S., Unterleuthner, D., Unger, C., Kramer, N., Hengstschläger, M., Kenner, L., et al. (2016) · Journal of Cell Science · doi:10.1242/jcs.188102 · Cited by 389
“Cancer therapy for advanced cancers is far from being efficient to date (Scannell et al., 2012).”
BackgroundMirowski, P. (2018) · Social Studies of Science · doi:10.1177/0306312718772086 · Cited by 372
“Eroom’s Law reveals a linear decline in number of drugs approved per billion US$ from 1950 to the present (Scannell et al., 2012).”
Natural products for human health: an historical overview of the drug discovery approaches
Bernardini, S., Tiezzi, A., Laghezza Masci, V., & Ovidi, E. (2018) · Natural Product Research · doi:10.1080/14786419.2017.1356838 · Cited by 355
“Compounds are often selected from the libraries very quickly basing on their potency values (Scannell et al. 2012), but at the same time they can have a negative correlation concerning ADME/T (Adsorption, Distribution, Metabolism, Excretion/Toxicity) (Gleeson et al. 2011).”
BackgroundPeptide therapeutics: Targeting the undruggable space
Tsomaia, N. (2015) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2015.01.014 · Cited by 348
Therapies for rare diseases: therapeutic modalities, progress and challenges ahead
Tambuyzer, E., Vandendriessche, B., Austin, C. P., Brooks, P. J., Larsson, K., Miller Needleman, K. I., Valentine, J., Davies, K., Groft, S. C., Preti, R., et al. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0049-9 · Cited by 357
Deep learning in drug discovery: opportunities, challenges and future prospects
Lavecchia, A. (2019) · Drug Discovery Today · doi:10.1016/j.drudis.2019.07.006 · Cited by 353
Elucidating Compound Mechanism of Action by Network Perturbation Analysis
Woo, J. H., Shimoni, Y., Yang, W. S., Subramaniam, P., Iyer, A., Nicoletti, P., Rodríguez Martínez, M., López, G., Mattioli, M., Realubit, R., et al. (2015) · Cell · doi:10.1016/j.cell.2015.05.056 · Cited by 351
“Its elucidation is critical in assessing both on-target compound activity as well as off-target effects associated with potential toxicity, thus providing critical insight into the two major challenges of drug development (Scannell et al., 2012).”
How Beyond Rule of 5 Drugs and Clinical Candidates Bind to Their Targets
Doak, B. C., Zheng, J., Dobritzsch, D., & Kihlberg, J. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b01286 · Cited by 335
A Decade of FDA-Approved Drugs (2010–2019): Trends and Future Directions
Brown, D. G., & Wobst, H. J. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01516 · Cited by 320
Performance assessment and economic analysis of a human Liver-Chip for predictive toxicology
Ewart, L., Apostolou, A., Briggs, S. A., Carman, C. V., Chaff, J. T., Heng, A. R., Jadalannagari, S., Janardhanan, J., Jang, K.-J., Joshipura, S. R., et al. (2022) · Communications Medicine · doi:10.1038/s43856-022-00209-1 · Cited by 337
Self-citationChanging R&D models in research-based pharmaceutical companies
Schuhmacher, A., Gassmann, O., & Hinder, M. (2016) · Journal of Translational Medicine · doi:10.1186/s12967-016-0838-4 · Cited by 286
“• an inadequate number of projects in early R&D phases [12], • technically more complex research for new drug targets and subsequent preclinical and clinical studies [19], • a higher burden for approval and reimbursement of NMEs in view of the already approved drugs, • a lower risk tolerance of both regulators and soc…”
BackgroundBordon, K. D. C. F., Cologna, C. T., Fornari-Baldo, E. C., Pinheiro-Júnior, E. L., Cerni, F. A., Amorim, F. G., Anjolette, F. A. P., Cordeiro, F. A., Wiezel, G. A., Cardoso, I. A., et al. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.01132 · Cited by 303
“First, new therapeutic drugs must achieve very high standards to be accepted, since theymay have to compete with older and well-known drugs on the market, which may be more effective and cheaper, in most cases (because of the expired patent, for instance) (Scannell et al., 2012).”
BackgroundEfficiencies of platform clinical trials: A vision of the future
Saville, B. R., & Berry, S. M. (2016) · Clinical Trials · doi:10.1177/1740774515626362 · Cited by 315
“Enrollment rate is 200 patients/year, and there is a 3-month lag in between trials for strategies (1) and (2).”
BackgroundA review of computational drug repurposing
Park, K. (2019) · Translational and Clinical Pharmacology · doi:10.12793/tcp.2019.27.2.59 · Cited by 300
“It is known that the total average development cost for a new drug ranges from $2 to $3 billion and the total development time takes at least 13–15 years.[1] Further, it suffers from a high attrition rate.”
BackgroundAnimal to human translation: a systematic scoping review of reported concordance rates
Leenaars, C. H. C., Kouwenaar, C., Stafleu, F. R., Bleich, A., Ritskes-Hoitinga, M., De Vries, R. B. M., & Meijboom, F. L. B. (2019) · Journal of Translational Medicine · doi:10.1186/s12967-019-1976-2 · Cited by 314
A Data-Driven Approach to Predicting Successes and Failures of Clinical Trials
Gayvert, K. M., Madhukar, N. S., & Elemento, O. (2016) · Cell chemical biology · doi:10.1016/j.chembiol.2016.07.023 · Cited by 310
“This is occurring despite improvements in all stages of the drug development pipeline (Scannell et al., 2012).”
BackgroundThe Opioid Epidemic: Crisis and Solutions
Skolnick, P. (2018) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010617-052534 · Cited by 307
Cell permeability beyond the rule of 5
Matsson, P., Doak, B. C., Over, B., & Kihlberg, J. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2016.03.013 · Cited by 297
Ionic liquids as a potential tool for drug delivery systems
Adawiyah, N., Moniruzzaman, M., Hawatulaila, S., & Goto, M. (2016) · MedChemComm · doi:10.1039/c6md00358c · Cited by 292
Industrial Applications of the Diels–Alder Reaction
Funel, J., & Abele, S. (2013) · Angewandte Chemie International Edition · doi:10.1002/anie.201201636 · Cited by 292
Marx, U. (2016) · ALTEX · doi:10.14573/altex.1603161 · Cited by 295
“…has declined more than fifteen-fold, as indicated by the respective increase in inflation-adjusted average spending from $179 million per successful drug (including the costs of failures) in the 1970s to $2.6 billion in the twenty-first century (Scannell et al., 2012; Tufts CSDD, 2014) (Fig.”
InfluentialMendelian randomization for studying the effects of perturbing drug targets
Gill, D., Georgakis, M. K., Walker, V. M., Schmidt, A. F., Gkatzionis, A., Freitag, D. F., Finan, C., Hingorani, A. D., Howson, J. M. M., Burgess, S., et al. (2021) · Wellcome Open Research · doi:10.12688/wellcomeopenres.16544.2 · Cited by 308
Hernandez, J. J., Pryszlak, M., Smith, L., Yanchus, C., Kurji, N., Shahani, V. M., & Molinski, S. V. (2017) · Frontiers in Oncology · doi:10.3389/fonc.2017.00273 · Cited by 281
“This trend, termed “Eroom’s Law,” describes the inverse correlation of large monetary input into drug development and the deceleration of drug discovery (32).”
BackgroundWhen Quality Beats Quantity: Decision Theory, Drug Discovery, and the Reproducibility Crisis
Scannell, J. W., & Bosley, J. (2016) · PLOS ONE · doi:10.1371/journal.pone.0147215 · Cited by 279
“Second, such explanations may underestimate the difficulty of historical discoveries [77] [24] [1].”
BackgroundResultInfluentialSelf-citationNatural products: An upcoming therapeutic approach to cancer
Dutta, S., Mahalanobish, S., Saha, S., Ghosh, S., & Sil, P. C. (2019) · Food and Chemical Toxicology · doi:10.1016/j.fct.2019.04.012 · Cited by 259
Mendelian randomization for studying the effects of perturbing drug targets
Gill, D., Georgakis, M. K., Walker, V. M., Schmidt, A. F., Gkatzionis, A., Freitag, D. F., Finan, C., Hingorani, A. D., Howson, J. M. M., Burgess, S., et al. (2021) · Wellcome Open Research · doi:10.12688/wellcomeopenres.16544.1 · Cited by 266
The integration of flow reactors into synthetic organic chemistry
Baxendale, I. R. (2013) · Journal of Chemical Technology & Biotechnology · doi:10.1002/jctb.4012 · Cited by 255
A safe lithium mimetic for bipolar disorder
Singh, N., Halliday, A. C., Thomas, J. M., Kuznetsova, O. V., Baldwin, R., Woon, E. C. Y., Aley, P. K., Antoniadou, I., Sharp, T., Vasudevan, S. R., et al. (2013) · Nature Communications · doi:10.1038/ncomms2320 · Cited by 258
Poornima, P., Kumar, J. D., Zhao, Q., Blunder, M., & Efferth, T. (2016) · Pharmacological Research · doi:10.1016/j.phrs.2016.06.018 · Cited by 248
Stock, K., Estrada, M. F., Vidic, S., Gjerde, K., Rudisch, A., Santo, V. E., Barbier, M., Blom, S., Arundkar, S. C., Selvam, I., et al. (2016) · Scientific Reports · doi:10.1038/srep28951 · Cited by 253
“ECM embedded cultures were established in, (1) Matrigel, a basal membrane extract that induces polarization of normal epithelial cells15, and would thus reflect a localized tumor environment, (2) collagen I as an interstitial stroma matrix component, providing an invasive growth environment16, and, (3) a 1:1 mix of bo…”
BackgroundMethodInfluentialContribution of NIH funding to new drug approvals 2010–2016
Galkina Cleary, E., Beierlein, J. M., Khanuja, N. S., McNamee, L. M., & Ledley, F. D. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1715368115 · Cited by 248
Improving the odds of drug development success through human genomics: modelling study
Hingorani, A. D., Kuan, V., Finan, C., Kruger, F. A., Gaulton, A., Chopade, S., Sofat, R., MacAllister, R. J., Overington, J. P., Hemingway, H., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-54849-w · Cited by 247
Meanwell, N. A. (2016) · Chemical Research in Toxicology · doi:10.1021/acs.chemrestox.6b00043 · Cited by 239
From single drug targets to synergistic network pharmacology in ischemic stroke
Casas, A. I., Hassan, A. A., Larsen, S. J., Gomez-Rangel, V., Elbatreek, M., Kleikers, P. W. M., Guney, E., Egea, J., López, M. G., Baumbach, J., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1820799116 · Cited by 239
“Not surprisingly, drug discovery has thus become increasingly inefficient (4).”
BackgroundComputational pharmaceutics - A new paradigm of drug delivery
Wang, W., Ye, Z., Gao, H., & Ouyang, D. (2021) · Journal of Controlled Release · doi:10.1016/j.jconrel.2021.08.030 · Cited by 218
Azizgolshani, H., Coppeta, J. R., Vedula, E. M., Marr, E. E., Cain, B. P., Luu, R. J., Lech, M. P., Kann, S. H., Mulhern, T. J., Tandon, V., et al. (2021) · Lab on a Chip · doi:10.1039/d1lc00067e · Cited by 225
Understanding Cryptic Pocket Formation in Protein Targets by Enhanced Sampling Simulations
Oleinikovas, V., Saladino, G., Cossins, B. P., & Gervasio, F. L. (2016) · Journal of the American Chemical Society · doi:10.1021/jacs.6b05425 · Cited by 217
Powley, I. R., Patel, M., Miles, G., Pringle, H., Howells, L., Thomas, A., Kettleborough, C., Bryans, J., Hammonds, T., MacFarlane, M., et al. (2020) · British Journal of Cancer · doi:10.1038/s41416-019-0672-6 · Cited by 218
Overcoming Drug Development Bottlenecks With Repurposing: Old drugs learn new tricks
Strittmatter, S. M. (2014) · Nature Medicine · doi:10.1038/nm.3595 · Cited by 222
Harvey, A. L. (2014) · Toxicon · doi:10.1016/j.toxicon.2014.10.020 · Cited by 210
“Scannell et al. (2012) postulate that a focus on cancer or on neglected diseases may be fruitful because the ‘better than the Beatles’ problem will be less when there are few existing treatments to contend with and because the attitudes of the regulatory authorities may be more encouraging towards…”
BackgroundInfluentialPhenome-Wide Association Studies as a Tool to Advance Precision Medicine
Denny, J. C., Bastarache, L., & Roden, D. M. (2016) · Annual Review of Genomics and Human Genetics · doi:10.1146/annurev-genom-090314-024956 · Cited by 232
“The cost of generating new therapeutics has risen dramatically over the past 60 years, with each new drug costing approximately 80 times as much in 2010 as it did in 1960, in inflation-adjusted terms (69).”
BackgroundThe Pharmaceutical Industry and the Future of Drug Development
Taylor, D. (2015) · Pharmaceuticals in the Environment · doi:10.1039/9781782622345-00001 · Cited by 192
Phage therapy—constraints and possibilities
Nilsson, A. S. (2014) · Upsala Journal of Medical Sciences · doi:10.3109/03009734.2014.902878 · Cited by 206
Dendrimers in combination with natural products and analogues as anti-cancer agents
Mignani, S., Rodrigues, J., Tomas, H., Zablocka, M., Shi, X., Caminade, A.-M., & Majoral, J.-P. (2018) · Chemical Society Reviews · doi:10.1039/c7cs00550d · Cited by 219
Nanotheranostics for personalized medicine
Kim, T. H., Lee, S., & Chen, X. (2013) · Expert Review of Molecular Diagnostics · doi:10.1586/erm.13.15 · Cited by 222
Weth, F. R., Hoggarth, G. B., Weth, A. F., Paterson, E., White, M. P. J., Tan, S. T., Peng, L., & Gray, C. (2024) · British Journal of Cancer · doi:10.1038/s41416-023-02502-9 · Cited by 197
Machine learning-aided generative molecular design
Du, Y., Jamasb, A. R., Guo, J., Fu, T., Harris, C., Wang, Y., Duan, C., Liò, P., Schwaller, P., & Blundell, T. L. (2024) · Nature Machine Intelligence · doi:10.1038/s42256-024-00843-5 · Cited by 169
Pirintsos, S., Panagiotopoulos, A., Bariotakis, M., Daskalakis, V., Lionis, C., Sourvinos, G., Karakasiliotis, I., Kampa, M., & Castanas, E. (2022) · Molecules · doi:10.3390/molecules27134060 · Cited by 167
“About 114,000 extracts from an estimated 35,000 plant samples (representing 12,000–13,000 species), collected mostly from temperate regions of the world, had been screened against a number of tumor systems between 1960 and 1982 [27,86,87].”
BackgroundInfluentialDeveloping predictive assays: The phenotypic screening “rule of 3”
Vincent, F., Loria, P., Pregel, M., Stanton, R., Kitching, L., Nocka, K., Doyonnas, R., Steppan, C., Gilbert, A., Schroeter, T., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aab1201 · Cited by 199
“M C D O N A L D / C IE N C E T R A N S L A T IO N A L M E D IC IN E PHENOTYPE DRIVE Over the past decade, several commentaries have referred to a productivity crisis within the pharmaceutical industry (1, 2).”
BackgroundHigh-Content Monitoring of Drug Effects in a 3D Spheroid Model
Mittler, F., Obeïd, P., Rulina, A. V., Haguet, V., Gidrol, X., & Balakirev, M. Y. (2017) · Frontiers in Oncology · doi:10.3389/fonc.2017.00293 · Cited by 194
“Biotechnol Bioeng (2003) 83(2):173–80.”
InfluentialScaffold Diversity Synthesis and Its Application in Probe and Drug Discovery
Garcia‐Castro, M., Zimmermann, S., Sankar, M. G., & Kumar, K. (2016) · Angewandte Chemie International Edition · doi:10.1002/anie.201508818 · Cited by 199
Cheminformatic comparison of approved drugs from natural product versus synthetic origins
Stratton, C. F., Newman, D. J., & Tan, D. S. (2015) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2015.07.014 · Cited by 191
Bunker, A., Magarkar, A., & Viitala, T. (2016) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2016.02.025 · Cited by 190
Modeling Human Disease with Pluripotent Stem Cells: from Genome Association to Function
Merkle, F. T., & Eggan, K. (2013) · Cell Stem Cell · doi:10.1016/j.stem.2013.05.016 · Cited by 185
“Similarly, the majority of drugs that are effective in mice have failed in human clinical trials (Scannell et al., 2012).”
BackgroundLow, Z. Y., Farouk, I. A., & Lal, S. K. (2020) · Viruses · doi:10.3390/v12091058 · Cited by 180
“This condition further exacerbates as the number of new drugs approved per billion USD deteriorate significantly to below 1 after the year of 2000, according to Eroom’s Law, indicating higher spending on research and development with significant less new molecular entities approval per year [43].”
BackgroundOpportunities and challenges in translational science
Austin, C. P. (2021) · Clinical and Translational Science · doi:10.1111/cts.13055 · Cited by 188
Tang, J., & Aittokallio, T. (2014) · Current Pharmaceutical Design · doi:10.2174/13816128113199990470 · Cited by 175
“Over the past decades, there has been a massive progress in many scientific and technological developments in pharmaceutical research; yet, over the same time period, the number of new drugs approved or successfully translated into clinical use has significantly declined, despite of massive investment on drug research…”
BackgroundResearch Funding: the Case for a Modified Lottery
Fang, F. C., & Casadevall, A. (2016) · mBio · doi:10.1128/mbio.00422-16 · Cited by 160
“In this regard, there is evidence for increasing inefficiency in the translation of basic discovery into medical goods (54, 55).”
Animal testing and its alternatives—the most important omics is economics
Meigs, L. (2018) · ALTEX · doi:10.14573/altex.1807041 · Cited by 184
Molecular inflation, attrition and the rule of five
Leeson, P. D. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2016.01.018 · Cited by 179
AI-based language models powering drug discovery and development
Liu, Z., Roberts, R. A., Lal-Nag, M., Chen, X., Huang, R., & Tong, W. (2021) · Drug Discovery Today · doi:10.1016/j.drudis.2021.06.009 · Cited by 167
Metadata
- Authors
- Scannell, J. W., Blanckley, A., Boldon, H., & Warrington, B.
- Corresponding author
- Scannell, Jack W.
- ORCID
- Scannell, Jack W.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2012-03
- Volume
- 11
- Issue
- 3
- Pages
- 191-200
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W2028279608
- Cited by
- 1,981
- References
- 85
- Citations by year
- 2026: 135 · 2025: 123 · 2024: 144 · 2023: 126 · 2022: 141 · 2021: 173 · 2020: 178 · 2019: 144 · 2018: 138 · 2017: 133 · 2016: 155 · 2015: 136 · 2014: 108 · 2013: 103 · 2012: 41
- FWCI
- 47.94
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Pharmaceutical Economics and Policy
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Health and Medical Research Impacts
- Health Sciences › Nursing › Issues, ethics and legal aspects › Pharmaceutical industry and healthcare
- Keywords
- new drug approvals, drug approval rates, drug development costs, regulatory policy, drug regulation, basic research
- MeSH terms
- Animals, Drug Industry, Pharmaceutical Preparations, Humans, Research, Drug Delivery Systems, Efficiency, Organizational
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.